The effect of denosumab for the treatment of osteoporosis in hemodialysis patients

The effect of denosumab for the treatment of osteoporosis in hemodialysis patients - The effect of denosumab on hemodialysis patients with osteoporosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014458

Enrollment

Registered

2014-07-02

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Patients will be injected subcutaneously with 60 mg of denosumab every 6 months for 24 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: hemodialysis patient with osteoporosis including these Criteria 1)intactPTH 60-240 pg/ml 2)cCa 8.5-10.0 mg/dl

Exclusion criteria

Exclusion criteria: Patient who have the contraindication for denosumab.

Design outcomes

Primary

Measure	Time frame
Change in bone mineral density (BMD) at lumbar supine and femoral neck and TRACP-5b	—

Secondary

Measure	Time frame
Change in Ca, P, intact-PTH and side effect	—

Countries

Japan

Contacts

Public ContactHironobu Inoue

Saiseikai Kumamoto Hospital Department of nephrology and urology

hironobu-inoue@saiseikaikumamoto.jp096-351-8000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026